Abstract
The Proton Pump Inhibitors versus Histamine-2 Receptor Blockers for Ulcer Prophylaxis Therapy in the Intensive Care Unit (PEPTIC) study1 has now been published.2 With 26 828 participants, the PEPTIC trial is the largest clinical trial ever conducted in intensive care medicine and provides very precise estimates of the likely range of possible treatment effects associated with proton pump inhibitors versus histamine-2 receptor blockers. In this issue of Critical Care and Resuscitation, Young and colleagues3 discuss the meaning and implications of this extraordinary trial in detail in a not-to-be-missed editorial.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
